The heart pump can now be
used in pediatric patients with advanced refractory left ventricular heart
failure, giving physicians more options for treating the pediatric population
awaiting a heart transplant or ineligible for receiving a transplant due to
complications, according to a news release.
Heart Mate 3 initially received U.S. approval in
2017 for adults awaiting a heart transplant, then it received long-term use
approval for adults in 2018. The left ventricular assist device (LVAD) is
implanted to pump blood through the body for those who have hearts too weak to
do so in their own.
Abbott Park, Ill.-based Abbott said the updated
labeling follows a trend of pediatric innovations for the company, with its
Masters HP heart valve approved in 2018 and its Amplatzer Piccolo occluder
cleared in 2019, both for pediatric populations.
“For families with children battling chronic
diseases the future is often bleak. As physicians, we see the fear in the eyes
of not only the child, but also the mothers and fathers,” divisional VP of
global medical affairs in Abbott’s heart failure business Dr. Robert L. Kormos
said in the release. “Imagine a child with a heart condition that
does not allow them to play with friends, sing or run. Innovations, such as the
Heart Mate 3, can lessen the crippling effects of heart failure and allow that
child to live a more normal life.”
Many children and adolescents with congestive heart
failure require a heart
transplant or mechanical device implant to survive. The Heart Mate 3 left
ventricular assist device (LVAD) – or heart pump – is an implantable device
that pumps blood through the body in people whose heart is too weak to do so on
its own. The Heart Mate 3 pump was initially approved in the United States in
2017 for adults awaiting a heart transplant and received FDA approval for
long-term use in adults in 2018. In the largest LVAD trial in the world, the
Heart Mate 3 pump showed a survival rate of 79% at two years – an outcome
comparable to patients receiving a heart transplant.
"For families with children battling chronic
diseases the future is often bleak. As physicians, we see the fear in the eyes
of not only the child, but also the mothers and fathers," said Robert L.
Kormos, M.D., divisional vice president, global medical affairs, Abbott's heart failure business.
"Imagine a child with a heart condition that does not allow them to play
with friends, sing or run. Innovations, such as the Heart Mate 3, can lessen
the crippling effects of heart failure and allow that child to live a more
normal life."
Contact: cardionheart@gmail.com
No comments:
Post a Comment